CD274 and non-small cell lung carcinoma: The purpose of this systematic review (registration: UMIN-CTR no. UMIN000039784) was to compare the efficacy and safety of Niv+Ipi in PD-L1-positive advanced NSCLC derived from publicly available RCTs based on existing regimens with immunotherapies, such as Pem, Pem+PBC, and Niv with PBC as a common comparator, and to rank the efficacy and safety of these therapeutic regimens using the statistical Bayesian NMA approach.